Most patients survive acute myocardial infarction (MI). Yet this encouraging development
has certain drawbacks: heart failure (HF) prevalence is increasing and patients affected tend …

Abstract Purpose of Review Ischemic cardiomyopathy refers to systolic left ventricular
dysfunction in the setting of obstructive coronary artery disease and represents the most …

Myocardial infarction (MI) is the leading cause of death and morbidity worldwide, with an
incidence relatively high in developed countries and rapidly growing in developing …

MSCs products as well as their derived extracellular vesicles, are currently being explored
as advanced biologics in cell-based therapies with high expectations for their clinical use in …

Aims ST-segment elevation myocardial infarction (STEMI) is associated with an intense
acute inflammatory response and an increased risk of death and heart failure (HF). In this …

Owing to recent advances in early reperfusion strategies, pharmacological therapy,
standardized care, and the identification of vulnerable patient subsets, the prognosis of …

Cell-based therapies offer an exciting and novel treatment for heart repair following
myocardial infarction (MI). However, these therapies often suffer from poor cell viability and …

Myocardial infarction is the first cause of worldwide mortality, with an increasing incidence
also reported in developing countries. Over the past decades, preclinical research and …

ST-segment elevation myocardial infarction (STEMI) remains a significant source of
morbidity and mortality worldwide. Despite advances in treatment leading to a significant …

Heart failure secondary to cardiomyocyte loss and/or dysfunction is the number one killer
worldwide. The field of myocardial regeneration with its far-reaching primary goal of cardiac …